Arthur Coury Joins Biotectix as Member of Scientific Advisory Board
“Art is an internationally recognized pioneer in the field of implantable biomaterials,” noted Dr. James Arps, General Manager at Biotectix, “he brings a wealth of highly-relevant industry knowledge that will help our company execute on the key technical, commercialization, and regulatory strategies that will ensure the success of our business.”
Dr. Coury’s industrial career has included positions as Director of Polymer Technology and Research Fellow at Medtronic, Vice President, Research and Chief Scientific Officer at Focal, Inc. and Vice President, Biomaterials Research at Genzyme Corporation. His career focus has been polymeric biomaterials for medical products such as implantable electronic devices, hydrogel-based devices and drug delivery systems. A Fellow of the American Chemical Society, he holds over fifty distinct patents and has published and presented widely in his field. Dr. Coury earned a B.S. degree in chemistry from the University of Delaware, a Ph.D. in organic chemistry, and an M.B.A. from the University of Minnesota.
“I am pleased to be able to work with Biotectix as they continue to develop their conductive polymer technology in collaboration with partners in the medical device arena.” Dr. Coury went on to add, “I’ve long had an interest in the use of novel polymers for electrostimulation applications and have been impressed with the company’s progress and approach thus far.”
About Biotectix
Biotectix is developing a new class of conductive polymer materials and coatings for implantable devices and sensors that improve the safety, longevity, reliability, biological integration, and function of implantable biomedical devices. A number of benefits are driven by this platform technology without changing device size, shape, or implant procedure, including improved electrical performance, biocompatibility, and tissue response.
The technology addresses key limitations faced by the medical device industry including foreign body reactions, component stability, and long-term electrical performance in vivo. The materials are custom-designed for the specialized mechanical, electrical, and biological environments of the body, and provide an extremely high level of functional interfacing for medical electrodes. Biotectix was formed by Allied Minds, a private equity company, based on technology originally developed at the University of Michigan, Ann Arbor. The founders and inventors continue to develop and validate the technology through research, collaborations, and partnerships with leading companies and research institutions. For more information please visit www.biotectix.com
About Allied Minds
Allied Minds is a private equity-funded innovation company that forms, funds, manages and builds startups based on early-stage technology developed at renowned U.S. universities and national labs. We serve as a diversified holding company that supports our businesses with capital, management and shared services. Allied Minds is the premier firm to utilize this novel and fully-integrated approach to technology commercialization. Our investments span multiple business sectors and offer an attractive risk-return profile, a deliverable timeline and groundbreaking products and services. Our subsidiaries include BA Logix, Biotectix, Cephalogics, CryoXtract, Illumasonix, ProGDerm, Precision Biopsy, Purtein, RF Biocidics, SaltCheck, SciFluor Life Sciences, SiEnergy Systems, SoundCure and Spin Transfer Technologies. We don't just fund the startup. We are the startup. www.alliedminds.com
For further questions or additional information please contact:
James Arps
Vice President & General Manager
Biotectix, LLC an Allied Minds Company
734-585-5126Br>
jim.arps@biotectix.com
